CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 167 enrolled
Drug / intervention
SLCO1B1*5 allele testing, results reported at randomization +2 moregenetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01894230
NCT01894230N/ACompleted

Genetically Guided Statin Therapy to Improve Medication Adherence

Duke University·interventional·Posted Jul 10, 2013·Updated Jun 23, 2017

In Brief

A clinical study evaluating SLCO1B1*5 allele testing, results reported at randomization, SLCO1B1*5 allele testing, results reported at end of study, and 1 other intervention for Hypercholesterolemia and Hydroxy-methylglutaryl-coenzyme A (HMG Co-A) Reductase Inhibitors Adverse Reaction. Completed, enrolled 167 participants across 2 sites.

Detailed Summary

The purpose of this study is to examine if using genetics can improve statin adherence in patients who should be taking statins but are not because of prior side effects. This study will assist physicians/providers in making a personalized health care plan for prevention of cardiovascular disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 10, 2013
Enrollment StartJul 1, 2013
Primary CompletionApr 30, 2016
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 13.0 years ago

Interventions

SLCO1B1*5 allele testing, results reported at randomizationgenetic

Genetic testing for SLCO1B1\*5 allele and reporting of results to patient and provider at randomization

SLCO1B1*5 allele testing, results reported at end of studygenetic

Genetic testing for SLCO1B1\*5 allele and reporting of results to patient and provider at end of study

Genetic testing for SLCO1B1*5 allelegenetic

Blood test for SLCO1B1\*5 allele